Table 2 Clinicopathological features of patients eligible for adjuvant abemaciclib, adjuvant ribociclib, or non-eligible for adjuvant CDK4/6
Characteristic | Eligible for adjuvant ribociclib (N = 1068) | Eligible for adjuvant abemaciclib (N = 440) | Not eligible for any CDK4/6 inhibitor (N = 2031) | Overall population (N = 3103) | ||||
|---|---|---|---|---|---|---|---|---|
N | (%) | N | (%) | N | (%) | N | (%) | |
Age at diagnosis. years | ||||||||
Mean (SD) | 61.9 (14.1) | 62.6 (14.8) | 62.1 (12.3) | 62 (12.9) | ||||
Median (Min–Max) | 61.4 (25–95.3) | 62.1 (25–95.3) | 62.5 (27.8–94.8) | 62.3 (25–95.3) | ||||
Menopausal status at diagnosis | ||||||||
Menopaused | 709 | (71.0) | 289 | (70.8) | 1430 | (74.8) | 2141 | (73.5) |
Pre-menopaused | 289 | (29.0) | 119 | (29.2) | 483 | (25.2) | 773 | (26.5) |
Unknown | 70 | 32 | 118 | 189 | ||||
Germline BRCA mutation | ||||||||
BRCA1 | 7 | (5.9) | 5 | (9.1) | 3 | (1.3) | 10 | (2.9) |
BRCA2 | 12 | (10.2) | 6 | (10.9) | 14 | (6.1) | 27 | (7.8) |
Not detected | 99 | (83.9) | 44 | (80.0) | 211 | (92.5) | 310 | (89.3) |
Unknown/not performed | 950 | 385 | 1808 | 2756 | ||||
Nodal status at diagnosis | ||||||||
Negative | 715 | (67.5) | 214 | (49.2) | 1971 | (97.3) | 2689 | (87.0) |
Positive | 345 | (32.5) | 221 | (50.8) | 55 | (2.7) | 401 | (13.0) |
Unknown | 8 | 5 | 5 | 13 | ||||
Nodal status at surgery | ||||||||
Negative | 116 | (10.9) | 0 | (0) | 1905 | (95.3) | 2021 | (65.8) |
Positive | 952 | (89.1) | 440 | (100) | 94 | (4.7) | 1050 | (34.2) |
Unknown | 0 | 0 | 32 | 32 | ||||
Clinical stage (cAJCC) | ||||||||
0 | 1 | (0.1) | 0 | (0) | 4 | (0.2) | 5 | (0.2) |
IA | 408 | (38.8) | 87 | (20.2) | 1686 | (85.1) | 2094 | (69.0) |
IIA | 340 | (32.3) | 145 | (33.6) | 234 | (11.8) | 578 | (19.0) |
IIB | 182 | (17.3) | 116 | (26.9) | 39 | (2.0) | 221 | (7.3) |
IIIA | 28 | (2.7) | 21 | (4.9) | 4 | (0.2) | 32 | (1.1) |
IIIB | 81 | (7.7) | 52 | (12.1) | 13 | (0.7) | 94 | (3.1) |
IIIC | 11 | (1.0) | 10 | (2.3) | 0 | (0) | 11 | (0.4) |
Unknown | 17 | 9 | 51 | 68 | ||||
Pathological stage (pAJCC) | ||||||||
0 | 0 | (0) | 0 | (0) | 10 | (0.5) | 10 | (0.3) |
IA | 0 | (0) | 0 | (0) | 1684 | (84.2) | 1684 | (54.8) |
IB | 0 | (0) | 4 | (0.9) | 94 | (4.7) | 98 | (3.2) |
IIA | 472 | (44.2) | 62 | (14.1) | 211 | (10.6) | 683 | (22.2) |
IIB | 123 | (29.7) | 123 | (28.0) | 0 | (0) | 317 | (10.3) |
IIIA | 162 | (15.3) | 162 | (36.8) | 0 | (0) | 163 | (5.3) |
IIIB | 29 | (5.2) | 29 | (6.6) | 0 | (0) | 56 | (1.8) |
IIIC | 60 | (5.6) | 60 | (13.6) | 0 | (0) | 60 | (2.0) |
Unknown | 0 | 0 | 32 | 32 | ||||
Histological subtype | ||||||||
Ductal | 826 | (77.4) | 327 | (74.3) | 1571 | (77.3) | 2400 | (77.4) |
Lobular | 194 | (18.2) | 89 | (20.2) | 322 | (15.9) | 517 | (16.7) |
Other | 47 | (4.4) | 24 | (5.5) | 138 | (6.8) | 185 | (5.9) |
Unknown | 1 | 0 | 0 | 1 | ||||
Tumor grade (SBR) | ||||||||
I | 231 | (21.8) | 57 | (13.1) | 914 | (45.6) | 1146 | (37.4) |
II | 578 | (54.6) | 183 | (42.1) | 973 | (48.6) | 1551 | (50.6) |
III | 249 | (23.5) | 195 | (44.8) | 117 | (5.4) | 369 | (12.0) |
Unknown | 10 | 5 | 27 | 37 | ||||
Tumor progesterone receptor status | ||||||||
Positive | 908 | (85.0) | 372 | (84.6) | 1777 | (87.5) | 2689 | (86.7) |
Negative | 160 | (15.0) | 68 | (15.4) | 253 | (12.5) | 413 | (13.3) |
Unknown | 0 | 0 | 1 | 1 | ||||
Type of breast surgery | ||||||||
Tumorectomy | 507 | (47.5) | 138 | (31.4) | 1627 | (80.1) | 2136 | (68.8) |
Mastectomy | 559 | (52.3) | 301 | (68.4) | 404 | (19.9) | 965 | (31.1) |
Axillary lymph node dissection alone | 2 | (0.2) | 1 | (0.2) | 0 | (0) | 2 | (0.1) |
Type of axillary surgery | ||||||||
Axillary lymph node dissection | 664 | (62.3) | 356 | (80.9) | 456 | (22.8) | 1123 | (36.6) |
Sentinel lymph node dissection | 108 | (10.1) | 11 | (2.5) | 1446 | (72.2) | 1554 | (50.6) |
Both | 294 | (27.6) | 73 | (16.6) | 99 | (5.0) | 394 | (12.8) |
Unknown | 2 | 0 | 30 | 32 | ||||
